Logo

American Heart Association

  2
  0


Final ID:

The Discovery of the LDL-Receptor and It's Potential as a Target

  • Goldstein, Joseph  ( UTSW MEDICAL CTR , Dallas , Texas , United States )
  • Brown, Michael  ( UT SOUTHWESTERN MED CTR , Dallas , Texas , United States )
  • Ballantyne, Christie  ( BAYLOR COLLEGE MEDICINE , Houston , Texas , United States )
  • Author Disclosures:
    Joseph Goldstein: No Answer | Michael Brown: No Answer | Christie Ballantyne: DO have relevant financial relationships ; Independent Contractor:Abbott Diagnostic, Akcea, Amgen, Arrowhead, Ionis, Lilly, Merck, New Amsterdam, Novartis, Novo Nordisk:Active (exists now) ; Consultant:Abbott Diagnostic, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Eli Lilly, Esperion, Illumina, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Roche Diagnostic, TenSixteen Bio:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

The Future of Lipid Management: Using Lessons From Our Past

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
More abstracts from these authors:
Statins and memory

Zhao Bingxin, Ballantyne Christie, Nambi Vijay, Saseen Joseph

Resting Heart Rate Trajectories over 25 Years: Patterns, Predictors, and Prognostic Impact in the Atherosclerosis Risk in Communities (ARIC) Study

Meng Ning, Mok Yejin, Soliman Elsayed, Chen Lin, Ballantyne Christie, Solomon Scott, Matsushita Kuni

You have to be authorized to contact abstract author. Please, Login
Not Available